Brief reportWeaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan☆
References (11)
- et al.
Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionprognostic factors and survival
J Am Coll Cardiol
(2002) - et al.
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension
Chest
(2001) - et al.
Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension
Chest
(2003) - et al.
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial
Ann Intern Med
(1990) - et al.
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group
N Engl J Med
(1996)
There are more references available in the full text version of this article.
Cited by (81)
Treprostinil Effectiveness in Higher-Risk Pediatric Patients With Idiopathic and Heritable Pulmonary Arterial Hypertension
2024, Canadian Journal of CardiologyPediatric Pulmonary Arterial Hypertension
2020, Pediatric Clinics of North AmericaRight Heart Failure in Pediatric Pulmonary Hypertension
2018, Heart Failure in the Child and Young Adult: From Bench to BedsideRight Heart Failure in Pediatric Pulmonary Hypertension
2017, Heart Failure in the Child and Young Adult: From Bench to BedsidePulmonary Hypertension in Children
2016, Cardiology ClinicsCitation Excerpt :These results have been extrapolated to children.109,127–134 Bosentan therapy added on to epoprostenol in children allowed for a decrease in epoprostenol dose and its associated side effects.109 A more recent retrospective study of 86 children on bosentan for a median exposure of 14 months with and without concomitant therapy found that bosentan as part of an overall treatment strategy provided a sustained clinical and hemodynamic improvement that was overall well tolerated, and 2 year survival estimates were 91%.
Combination therapy in pulmonary arterial hypertension
2013, Clinics in Chest Medicine
- ☆
This research was supported by grant MO1 RR00069 from the General Clinical Research Centers Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland.
Copyright © 2004 Excerpta Medica Inc. All rights reserved.